Evidence strength for the context described on this page.
PEPTIDE ATLAS / MUSCLE & RECOVERY / SERMORELIN
Not FDA-approvedEarly human
Sermorelin
ALSO KNOWN ASGHRH(1–29)
A short GHRH analog with historical diagnostic/pediatric use but no currently marketed FDA-approved product.
01CATEGORYMuscle & recovery
02REGULATORY STATUSNot FDA-approved
03COMMON ROUTESubcutaneous injection
04DOSE BASISHistorical human use + reported clinic use
HOW TO USE THIS PAGE
Read the profile in the order that protects the decision.
- 01Verify what it is
Confirm the exact molecule, route, regulatory lane and actual human evidence.
- 02Read limits before dose
Unsupported claims, contraindications and uncertainty come before any protocol.
- 03Build the monitoring plan
Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.
This peptide does not have an FDA-approved product or dose for the claims described here. Research dosing and vendor protocols are not consumer prescribing guidance.
RESEARCH PASSPORT
The five facts to know first.
REVIEWED
JULY 2026
Status is product-, formulation- and indication-specific.
Trial, label or reported-practice basis is always named.
Official labels, regulators, trials and indexed literature where available.
Peptide hormones, growth factors and related substances may be prohibited.
Check Global DRO ↗OVERVIEW
What Sermorelin is.
A 29-amino-acid analog of endogenous GHRH. A prior FDA-approved product was discontinued; current compounded offerings are not themselves FDA-approved.
HOW IT IS THOUGHT TO WORK
Stimulates the pituitary to release growth hormone, requiring a functional hypothalamic-pituitary axis.
EFFECTS & EVIDENCE
What the evidence supports—and what it does not.
- Can provoke GH release
- Historical clinical utility differs from modern anti-aging marketing
- Longevity
- Routine adult body recomposition
- Improved sleep or recovery in healthy adults
- Equivalence of compounded products to a discontinued approved product
Evidence grade: Early human. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.
DOSAGE CONTEXT
Best available dosing range.
Historical human use + reported clinic useHistorical pediatric treatment dose: 30 mcg/kg subcutaneously at bedtime. Most current adult clinics publish 200–500 mcg subcutaneously once nightly, commonly starting near 200–300 mcg. The adult anti-aging range is compounded-practice information; there is no currently marketed FDA-approved sermorelin product.
BEST AVAILABLE GENERIC RANGE
Men and women.
The basis is named above. Reported-use ranges describe what clinics or communities publish; they are not proof of safety, efficacy, legality or product quality.
- Schedule in that source context
- Once nightly; clinics commonly reassess IGF-1 and symptoms after 8–12 weeks. Historical pediatric therapy used 30 mcg/kg nightly.
- How to interpret it
- Historical pediatric dosing does not validate adult anti-aging use. Current compounded products are not the discontinued FDA-approved product, and dose should be tied to endocrine diagnosis and monitoring.
ACTUAL HUMAN DOSES REPORTED IN THE RECORD
Research regimens may use different routes, diagnoses, formulations and monitoring. They cannot automatically be converted into a general protocol.
- Historical pediatric idiopathic GH-deficiency treatment: 30 mcg/kg subcutaneously once daily at bedtime.
- Route
- Subcutaneous injection
- Duration
- Historical pediatric therapy was longer term; adult clinic cycles are individualized
- Men & women
- No validated sex-based adult wellness dose; the same 200–500 mcg reported range is commonly used for men and women.
Clinician verification required. Always double-check the exact molecule or salt, concentration, route, volume, schedule, indication, patient-specific contraindications, interactions and applicable law with the prescribing clinician and dispensing pharmacy. A disclaimer does not make an unapproved product FDA-approved, and a reported-use range is not a prescription.
MONITORING
What should be tracked.
- IGF-1 and glucose if used in a legitimate endocrine context
- Symptoms of edema, headache or nerve compression
SAFETY
Risks, red flags and reasons to avoid it.
- Injection reactions
- Headache, flushing, dizziness and possible GH/IGF-1 effects
- Compounded-product potency and sterility variation
- Uncertain long-term safety
- Active malignancy
- Pregnancy
- Use without endocrine evaluation
- Claims that 'natural GH release' means risk-free
Stop and seek careGet urgent medical help for trouble breathing, facial or throat swelling, chest pain, fainting, severe persistent abdominal pain, neurologic changes, severe hypoglycemia, uncontrolled vomiting or a prolonged painful erection.
CLINICIAN VISIT CHECKLIST
Six questions worth bringing with you.
Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.
Name the diagnosis or target, how it will be measured and the realistic time to reassess.
Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.
Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.
Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.
Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.
Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.
PRIMARY SOURCES
Read the record yourself.
We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. A source supports the specific statement beside it—not every claim made about the molecule.
PRODUCTS & TREATMENT ACCESS
There is no product we can responsibly recommend.
Available through compounding channels; no current FDA-approved sermorelin drug product.
A compound can have legitimate historical pharmacology without having an approved modern anti-aging indication.
Evidence before affiliate revenue.
We do not rank or sell unapproved research peptides. Use the Atlas to discuss safer, evidence-backed alternatives with a qualified clinician.
Explore evidence-backed options →NEXT STEP